372 related articles for article (PubMed ID: 26617778)
21. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
[TBL] [Abstract][Full Text] [Related]
22. Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
Yeo SG; Kim DY; Park JW; Choi HS; Oh JH; Kim SY; Chang HJ; Kim TH; Sohn DK
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):856-62. PubMed ID: 21300482
[TBL] [Abstract][Full Text] [Related]
23. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
[TBL] [Abstract][Full Text] [Related]
24. Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.
Fokas E; Conradi L; Weiss C; Sprenger T; Middel P; Rau T; Dellas K; Kitz J; Rödel F; Sauer R; Rüschoff J; Beissbarth T; Arnold D; Ghadimi BM; Rödel C; Liersch T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):992-9. PubMed ID: 24210078
[TBL] [Abstract][Full Text] [Related]
25. Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer.
Qiu HZ; Wu B; Xiao Y; Lin GL
Colorectal Dis; 2011 Dec; 13(12):1353-60. PubMed ID: 21689282
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of treatment response and tissue necrosis as prognostic indicators following neoadjuvant chemoradiotherapy in rectal cancer patients.
Jung JH; An HJ; Kim HJ; Lee J; Lee KM; Kim SH; Cho HM; Shim BY
Korean J Intern Med; 2016 Jan; 31(1):134-44. PubMed ID: 26767867
[TBL] [Abstract][Full Text] [Related]
27. [Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy].
Cai C; Wang J; Zhong Z; Dai Z; Wang Q; Dong W; Shi H; Liu Q; DU J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):36-43. PubMed ID: 28436629
[TBL] [Abstract][Full Text] [Related]
28. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
29. Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer.
Shim BY; Jung JH; Lee KM; Kim HJ; Hong SH; Kim SH; Sun DS; Cho HM
Int J Colorectal Dis; 2013 Mar; 28(3):375-83. PubMed ID: 22847606
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer.
Yaghobi Joybari A; Azadeh P; Babaei S; Hosseini Kamal F
Pathol Oncol Res; 2019 Oct; 25(4):1599-1605. PubMed ID: 30712194
[TBL] [Abstract][Full Text] [Related]
31. Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer.
Huang MY; Lee HH; Tsai HL; Huang CW; Yeh YS; Ma CJ; Huang CM; Chen CY; Huang JJ; Wang JY
Radiat Oncol; 2018 Mar; 13(1):53. PubMed ID: 29587797
[TBL] [Abstract][Full Text] [Related]
32. Role of Neoadjuvant Radio-chemotherapy for the Treatment of High Rectal Cancer.
Treder M; Janssen S; Holländer NH; Schild SE; Rades D
Anticancer Res; 2018 Sep; 38(9):5371-5377. PubMed ID: 30194191
[TBL] [Abstract][Full Text] [Related]
33. Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series.
Sastre J; Serrano JJ; Fernández C; Ramirez C; Ortega L; García-Paredes B; Corona J; Alfonso R; Córdoba S; Díaz-Rubio E
Clin Colorectal Cancer; 2016 Jun; 15(2):128-34. PubMed ID: 26385572
[TBL] [Abstract][Full Text] [Related]
34. Is the pathological regression level of metastatic lymph nodes associated with oncologic outcomes following preoperative chemoradiotherapy in rectal cancer?
Choi JP; Kim SJ; Park IJ; Hong SM; Lee JL; Yoon YS; Kim CW; Lim SB; Lee JB; Yu CS; Kim JC
Oncotarget; 2017 Feb; 8(6):10375-10384. PubMed ID: 28060748
[TBL] [Abstract][Full Text] [Related]
35. Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in rectal cancer.
Hwang K; Park IJ; Yu CS; Lim SB; Lee JL; Yoon YS; Kim CW; Kim JC
World J Gastroenterol; 2015 Jan; 21(2):563-70. PubMed ID: 25593475
[TBL] [Abstract][Full Text] [Related]
36. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S
J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095
[TBL] [Abstract][Full Text] [Related]
37. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
[TBL] [Abstract][Full Text] [Related]
38. Expression of hypoxia-inducible factor 1α predicts clinical outcome after preoperative hyperthermo-chemoradiotherapy for locally advanced rectal cancer.
Shioya M; Takahashi T; Ishikawa H; Sakurai H; Ebara T; Suzuki Y; Saitoh J; Ohno T; Asao T; Kuwano H; Nakano T
J Radiat Res; 2011; 52(6):821-7. PubMed ID: 22104271
[TBL] [Abstract][Full Text] [Related]
39. Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis.
Meng X; Wang R; Huang Z; Zhang J; Feng R; Xu X; Zhu K; Dou X; Chen D; Yu J
Cancer Sci; 2014 Jul; 105(7):818-24. PubMed ID: 24730770
[TBL] [Abstract][Full Text] [Related]
40. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
